Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01991379 · ClinicalTrials.gov registry record · Phase 1

MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

A Phase 1 study of Gastrointestinal Stromal Tumor (GIST), sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
Phase 1
Development phase
75
Enrollment target
1
Study location

NCT01991379 is a Phase 1 study of Gastrointestinal Stromal Tumor (GIST) that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 75 participants, below the 182-participant average among 6 other Gastrointestinal Stromal Tumor (GIST) trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01991379, a Phase 1 study of Gastrointestinal Stromal Tumor (GIST), is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
75 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the effects, good and/or bad, of MEK162 and imatinib on the patient and on Gastrointestinal Stromal Tumor (GIST). Funding Source - FDA OOPD, Array/Pfizer

Conditions Studied

Gastrointestinal Stromal Tumor (GIST)

Interventions

  • OTHER Blood draws
  • PROCEDURE biopsy
  • DRUG MEK162
  • DRUG Imatinib Mesylate (Gleevec®; STI571; NSC #716051)

Study Locations (1)

New York

  • Memorial Sloan Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2013-11
Est. Completion 2026-11
Phase Phase 1

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01991379

The ClinicalTrials.gov registry entry for NCT01991379 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 182-participant average among 6 other Gastrointestinal Stromal Tumor (GIST) trials with a reported enrollment target (59% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Gastrointestinal Stromal Tumor (GIST) appearing as the primary indexed condition, and to 4 interventions - of which Blood draws is the first listed.

NCT01991379 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT01991379 about?

NCT01991379 is a clinical study titled "MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)". The purpose of this study is to evaluate the effects, good and/or bad, of MEK162 and imatinib on the patient and on Gastrointestinal Stromal Tumor (GIST). Funding Source - FDA OOPD, Array/Pfizer

What is the current status of trial NCT01991379?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2013-11. Estimated completion is 2026-11.

What conditions does trial NCT01991379 study?

This clinical trial studies the following conditions: Gastrointestinal Stromal Tumor (GIST).

What interventions are being tested in trial NCT01991379?

The interventions under investigation include: Blood draws (OTHER), biopsy (PROCEDURE), MEK162 (DRUG), Imatinib Mesylate (Gleevec®; STI571; NSC #716051) (DRUG).

Who is sponsoring clinical trial NCT01991379?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01991379 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastrointestinal Stromal Tumor (GIST)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Gastrointestinal Stromal Tumor (GIST)

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.